Dna-pk inhibitors
US-2017258789-A1 · Sep 14, 2017 · US
DNA-PK inhibitors
US10442791B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10442791-B2 |
| Application number | US-201815860304-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 2, 2018 |
| Priority date | Apr 24, 2012 |
| Publication date | Oct 15, 2019 |
| Grant date | Oct 15, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer in a patient comprising administering to said patient an effective amount of a compound selected from the group consisting of: or a pharmaceutically acceptable salts thereof, or a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 3. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 4. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 5. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 6. The method of claim 1 , wherein the cancer is breast cancer, colorectal cancer, gastric-esophageal cancer, fibrosarcoma, glioblastoma, hepatocellular cancer, head and neck cancer, melanoma, lung cancer, pancreatic cancer or prostate cancer. 7. A method of sensitizing a cell to an agent than induces a DNA lesion comprising contacting the cell with a compound selected from the group consisting of: or a pharmaceutically acceptable salts thereof, or a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof. 8. The method of claim 7 , wherein the compound is or a pharmaceutically acceptable salt thereof. 9. The method of claim 7 , wherein the compound is or a pharmaceutically acceptable salt thereof. 10. The method of claim 7 , wherein the compound is or a pharmaceutically acceptable salt thereof. 11. The method of claim 7 , wherein the compound is or a pharmaceutically acceptable salt thereof. 12. The method of claim 7 , wherein the agent that induces a DNA lesion is radiation therapy. 13. The method of claim 7 , wherein the agent that induces a DNA lesion is an anti-cancer chemotherapeutic agent.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10442791B2 cover?
- The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
- Who is the assignee on this patent?
- Vertex Pharma
- What technology area does this patent fall under?
- Primary CPC classification A61K31/506. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).